Serum albumin and risk of cardiovascular events in primary and secondary prevention: a systematic review of observational studies and Bayesian meta-regression analysis
- 20 Downloads
The predictive role of serum albumin (SA) has been evaluated in primary prevention studies. We want to assess the association of SA with the subsequent risk of cardiovascular events (CVE) in primary and secondary prevention studies. We performed a systematic review and Bayesian meta-regression analysis. Studies were identified by PubMed and EMBASE database using a combination of the following terms and MeSH terms: “serum albumin”, “myocardial infarction, “cardiovascular events”, “percutaneous coronary intervention” and “coronary restenosis”. No time restriction of the research was applied. Two experienced physicians reviewed data on outcome measures and assessed the quality rating. The main outcomes were CVE including myocardial infarction, coronary heart disease, percutaneous coronary intervention and coronary restenosis. 15 studies of SA and CVE were identified involving 65,077 subjects with a mean age of 57.89 ± 6.05 years and a mean follow-up of 9.4 (±5.56) years. Subjects under SA cut-off of 3.8 g/dL had a combined hazard ratio (HR) for CVE of 2.16 [95% confidence interval (CI) 1.93–2.45]. An increased risk for CVE was also evident using SA as a continuous variable (HR = 1.89, 95% CI 1.5–2.39). Females and males had a similar risk for CVE (HR 2.46, 95% CI 1.92–3.16, and HR 1.46, 95% CI 1.27–1.69, respectively). We found a similar risk of CVE between primary and secondary prevention studies (HR 1.79, 95% CI 1.5–2.17, and HR 2.47, 95% CI 2.24–2.75, respectively). Low SA levels are associated with an increased risk of CVE, not only in subjects free from CVE, but also in patients who already experienced a CVE.
KeywordsSerum albumin Cardiovascular events Thrombosis
Compliance with ethical standards
Conflict of interest
The authors report no conflict of interest.
Given the study type (review article), ethical approval was not necessary.
For this type of study formal consent is not required.
- 2.Paar M, Rossmann C, Nusshold C, Wagner T, Schlagenhauf A, Leschnik B, Oettl K, Koestenberger M, Cvirn G, Hallstrom S (2017) Anticoagulant action of low, physiologic, and high albumin levels in whole blood. PLoS ONE 12(8):e0182997. https://doi.org/10.1371/journal.pone.0182997 CrossRefPubMedPubMedCentralGoogle Scholar
- 7.Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 6(7):e1000100. https://doi.org/10.1371/journal.pmed.1000100 CrossRefPubMedPubMedCentralGoogle Scholar
- 21.Kucharska-Newton AM, Couper DJ, Pankow JS, Prineas RJ, Rea TD, Sotoodehnia N, Chakravarti A, Folsom AR, Siscovick DS, Rosamond WD (2009) Hemostasis, inflammation, and fatal and nonfatal coronary heart disease: long-term follow-up of the atherosclerosis risk in communities (ARIC) cohort. Arterioscler Thromb Vasc Biol 29(12):2182–2190. https://doi.org/10.1161/ATVBAHA.109.192740 CrossRefPubMedPubMedCentralGoogle Scholar
- 24.Wada H, Dohi T, Miyauchi K, Shitara J, Endo H, Doi S, Naito R, Konishi H, Tsuboi S, Ogita M, Kasai T, Okazaki S, Isoda K, Suwa S, Daida H (2017) Impact of serum albumin levels on long-term outcomes in patients undergoing percutaneous coronary intervention. Heart Vessels 32(9):1085–1092. https://doi.org/10.1007/s00380-017-0981-8 CrossRefPubMedGoogle Scholar
- 25.Gonzalez-Pacheco H, Amezcua-Guerra LM, Sandoval J, Martinez-Sanchez C, Ortiz-Leon XA, Pena-Cabral MA, Bojalil R (2017) Prognostic implications of serum albumin levels in patients with acute coronary syndromes. Am J Cardiol 119(7):951–958. https://doi.org/10.1016/j.amjcard.2016.11.054 CrossRefPubMedGoogle Scholar
- 26.Chien SC, Chen CY, Leu HB, Su CH, Yin WH, Tseng WK, Wu YW, Lin TH, Chang KC, Wang JH, Wu CC, Yeh HI, Chen JW (2017) Association of low serum albumin concentration and adverse cardiovascular events in stable coronary heart disease. Int J Cardiol 241:1–5. https://doi.org/10.1016/j.ijcard.2017.04.003 CrossRefPubMedGoogle Scholar
- 27.Kurtul A, Murat SN, Yarlioglues M, Duran M, Ocek AH, Koseoglu C, Celik IE, Kilic A, Aksoy O (2016) Usefulness of serum albumin concentration to predict high coronary SYNTAX score and in-hospital mortality in patients with acute coronary syndrome. Angiology 67(1):34–40. https://doi.org/10.1177/0003319715575220 CrossRefPubMedGoogle Scholar
- 28.Plakht Y, Gilutz H, Shiyovich A (2016) Decreased admission serum albumin level is an independent predictor of long-term mortality in hospital survivors of acute myocardial infarction. Soroka acute myocardial infarction II (SAMI-II) project. Int J Cardiol 219:20–24. https://doi.org/10.1016/j.ijcard.2016.05.067 CrossRefPubMedGoogle Scholar
- 29.Kurtul A, Ocek AH, Murat SN, Yarlioglues M, Demircelik MB, Duran M, Ergun G, Cay S (2015) Serum albumin levels on admission are associated with angiographic no-reflow after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction. Angiology 66(3):278–285. https://doi.org/10.1177/0003319714526035 CrossRefPubMedGoogle Scholar
- 30.Oduncu V, Erkol A, Karabay CY, Kurt M, Akgun T, Bulut M, Pala S, Kirma C (2013) The prognostic value of serum albumin levels on admission in patients with acute ST-segment elevation myocardial infarction undergoing a primary percutaneous coronary intervention. Coron Artery Dis 24(2):88–94. https://doi.org/10.1097/MCA.0b013e32835c46fd CrossRefPubMedGoogle Scholar
- 31.Su W, An T, Zhou Q, Huang Y, Zhang J, Zhang Y, Wei B, Sun X, Zou C, Lou K (2012) Serum albumin is a useful prognostic indicator and adds important information to NT-proBNP in a Chinese cohort of heart failure. Clin Biochem 45(7–8):561–565. https://doi.org/10.1016/j.clinbiochem.2012.02.010 CrossRefPubMedGoogle Scholar
- 32.Schillinger M, Exner M, Mlekusch W, Amighi J, Sabeti S, Schlager O, Wagner O, Minar E (2004) Serum albumin predicts cardiac adverse events in patients with advanced atherosclerosis—interrelation with traditional cardiovascular risk factors. Thromb Haemost 91(3):610–618. https://doi.org/10.1160/TH03-08-0504 CrossRefPubMedGoogle Scholar